Medications for Exudative Agerelated Macular Degeneration

5 results
  • beovu - brolucizumab injection, solution

    (Brolucizumab)
    Novartis Pharmaceuticals Corporation
    BEOVU is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).
  • byooviz - ranibizumab - nuna injection, solution

    (Ranibizumab-Nuna)
    Biogen Inc.
    Byooviz treats neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV).
  • cimerli - ranibizumab - eqrn injection, solution

    (Ranibizumab-Eqrn)
    Coherus Biosciences Inc
    Cimerli treats neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
  • lucentis - ranibizumab injection, solution

    (Ranibizumab)
    Genentech, Inc.
    Lucentis treats neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
  • vabysmo - faricimab injection, solution

    (Faricimab)
    Genentech, Inc.
    Vabysmo treats neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO) by inhibiting VEGF and angiopoietin-2.